Driving Translational Biomedical Research At The University Of Leicester
Lead Research Organisation:
University of Leicester
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Watson PJ
(2016)
Insights into the activation mechanism of class I HDAC complexes by inositol phosphates.
in Nature communications
Sathyasaikumar KV
(2018)
Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
in Methods in molecular biology (Clifton, N.J.)
Richards RL
(2015)
Persistent Staphylococcus aureus isolates from two independent cases of bacteremia display increased bacterial fitness and novel immune evasion phenotypes.
in Infection and immunity
Powley IR
(2020)
Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
in British journal of cancer
O'Leary AP
(2015)
Beta-Adrenoceptor Activation Reduces Both Dermal Microvascular Endothelial Cell Migration via a cAMP-Dependent Mechanism and Wound Angiogenesis.
in Journal of cellular physiology
Nettleship JE
(2015)
Transient expression in HEK 293 cells: an alternative to E. coli for the production of secreted and intracellular mammalian proteins.
in Methods in molecular biology (Clifton, N.J.)
Mitcheson DF
(2016)
A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase.
in Malaria journal
Maddison DC
(2015)
The kynurenine pathway and neurodegenerative disease.
in Seminars in cell & developmental biology
Le Provost GS
(2015)
ß2-adrenoceptor activation modulates skin wound healing processes to reduce scarring.
in The Journal of investigative dermatology
Karekla E
(2017)
Ex Vivo Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy.
in Cancer research
| Description | Breast Cancer Now preclinical catalyst award |
| Amount | £670,000 (GBP) |
| Organisation | Breast Cancer Now |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2021 |
| Description | EPSRC grant funding - Structural biology studies of COP9 signalosome. |
| Amount | £464,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2019 |
| Description | Explant collaboration with LifeArc |
| Amount | £320,000 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Explant collaboration with LifeArc - Further funding |
| Amount | £170,000 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Leicester Molecular Diagnostics |
| Amount | £15,000 (GBP) |
| Organisation | Hope Against Cancer (Rutland and Leicestershire) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 05/2018 |
| Description | Leicester Precision Medicine Institute studentship |
| Amount | £75,000 (GBP) |
| Organisation | University of Leicester |
| Department | Leicester Precision Medicine Institute |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | |
| Description | Neurodegeneration |
| Amount | $50,000 (USD) |
| Organisation | Michael J Fox Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 01/2016 |
| End | 01/2017 |
| Description | PDX project |
| Amount | £100,000 (GBP) |
| Organisation | Hope Against Cancer (Rutland and Leicestershire) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 04/2019 |
| Description | The Integrative Midlands Partnership for Biomedical Training (IMPACT) |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust Seed Awards in Science |
| Amount | £100,000 (GBP) |
| Funding ID | No 1079914/Z/15/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 08/2017 |
| Title | Explant project |
| Description | Using an ex vivo tissue explant to model patient responses to standard of care and novel drug therapies |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | The partnership with LifeArc and CR-UK Therapeutic Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. The pre-clinical model is now used with a wide variety of tumor types from lung to breast cancer, melanoma, colorectal cancer and endometrial cancer. A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. This project has received 3 rounds of follow on CiC funding (MC_PC_14117, MC_PC_15045, MC_PC_16051) - Updated in Feb2020. |
| Description | ADC synthesis |
| Organisation | Glythera Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of expertise and knowledge in the field. Provision of testing of novel ADC in cells in university labs by experts. |
| Collaborator Contribution | Synthesis of ADC molecules to specific target. |
| Impact | ADCs were produced and tested in cells. One manuscript is in preparation (anticipated publication date: early 2020) with results obtained with LD3 support. This project is ongoing as a basic research project - some additional interest has been shown by YuYu Pharma but this is not formal as yet but RF will be updated if this changes. Update Feb2020: in the process of licencing their patent (and file a divisional) to Stark Labs, a French biotech. A BBSRC grant application (£1,273,763) has been submitted (outcome in March 2020). |
| Start Year | 2015 |
| Description | Development of novel molecules for the treatment in non-Hodgkin's lymphoma |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | We have provided structural biology information and early cellular data to provide target validation. We are now supporting a GSK lead Med Chem programme by providing complex cellular and pre-clinical models. |
| Collaborator Contribution | GSK are providing on-going structural biology data to support a med chem programme and are also developing novel assays to demonstrate target engagement |
| Impact | It is hoped that this programme of work will ultimately result in a 'to clinic' drug. We have completed the FastTrack part of the GSK funding scheme, which was the early lead identification phase, and have progressed onto the GSK DPAC scheme which is the lead optimisation phase of the drug discovery pipeline. |
| Start Year | 2016 |
| Description | Development of novel small molecules for the treatment of non-Hodgkin's lymphoma |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | We have provided structural biology information and cell-based assay data to provide target validation. We are now supporting a GSK lead Med Chem programme by providing and running complex cellular and pre-clinical models such as explants, PDX models and PK/PD studies. |
| Collaborator Contribution | GSK are providing on-going structural biology data to support a medicinal chemistry programme and are also developing novel assays to demonstrate target engagement. |
| Impact | We have progressed from the GSK FastTrack award scheme of lead identification to the DPAC award scheme which is the lead optimisation phase of the drug discovery pipeline. Work is ongoing and is described in RF returns associated with other CiC grants to reduce the issue of multiple counting out outcomes. See MC_PC_15045 for the latest update. Added March 2021: We have progressed from the GSK Fast Track award scheme of lead identification to the DPAC award scheme which is the lead optimisation phase of the drug discovery pipeline. Within the DPAC scheme, we have moved from milestone 1 to milestone 2. It is hoped that this programme of work will ultimately result in a 'to clinic' drug. DPAc programme with GSK is still ongoing and progressing. Ana Sousa Manso has now left the LD3 team and is working as a Biology Project Coordinator for C4X Discovery Ltd, Manchester, United Kingdom (reported elsewhere in this application). Lead ID phase completed and progressing through Early Lead Optimisation. Evaluation point for progression to Late Lead Optimisation due in Q2 2020 - due to issues with medicinal chemistry (potency vs cell penetrance) the project has been terminated. GSK have given the rights, IP, synthesis info and background data for 5 compounds to UoL to use in further research projects and/or commercial development. A project management group has been established to maximise the outputs from this resource. Publications are in progress (jointly with GSK) - paper under review with Journal of Biochemistry (Feb 2021). |
| Start Year | 2016 |
| Description | Explant |
| Organisation | Cancer Research Technology (CRT) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment. |
| Collaborator Contribution | MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT will continue the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT will continue the collaboration under the name of LifeArc. |
| Impact | A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. The partnership with LifeArc and CR-UK Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. This project has received 3 rounds of follow on CiC funding (MC_PC_14117, MC_PC_15045, MC_PC_16051), generating >19-fold return on MRC CiC investment to date (Total £1.7M). Work on this project is also supporting work with GSK on the DPAc project to develop novel therapeutics for non-Hodgkin's lymphoma. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2015 |
| Description | Explant |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment. |
| Collaborator Contribution | MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT will continue the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT will continue the collaboration under the name of LifeArc. |
| Impact | A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. The partnership with LifeArc and CR-UK Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. This project has received 3 rounds of follow on CiC funding (MC_PC_14117, MC_PC_15045, MC_PC_16051), generating >19-fold return on MRC CiC investment to date (Total £1.7M). Work on this project is also supporting work with GSK on the DPAc project to develop novel therapeutics for non-Hodgkin's lymphoma. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2015 |
| Description | Explant |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Toxicology Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The development of tumour explant models for breast, lung and colorectal cancers (including liver metastases) to assess patient responses to current standard of care treatments. Follow on data shows that the model has a strong predictive power in prediction patient responses to therapy and survival. Going forward the plan is to use this as a 'test' system for novel compounds as part of their pre-clinical assessment. |
| Collaborator Contribution | MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT will continue the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT will continue the collaboration under the name of LifeArc. |
| Impact | A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. The partnership with LifeArc and CR-UK Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. This project has received 3 rounds of follow on CiC funding (MC_PC_14117, MC_PC_15045, MC_PC_16051), generating >19-fold return on MRC CiC investment to date (Total £1.7M). Work on this project is also supporting work with GSK on the DPAc project to develop novel therapeutics for non-Hodgkin's lymphoma. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2015 |
| Description | Patient-Derived Xenografts to enable personalised medicine |
| Organisation | Ono Pharmaceutical |
| Country | Japan |
| Sector | Private |
| PI Contribution | Working with individuals from Ono we have been using our access to a unique catalog of lymphoid cell lines to model resistance to BTK inhibition. Support has also been supplied for the development of PDX models of DLBCL. |
| Collaborator Contribution | A member of Ono staff has been working with in Leicester to develop and assay models of BTK resistance. |
| Impact | Outputs include - development of resistant lines, with full genetic analysis, the development of PDX models of lymphoid disease. Work ongoing with support of the Earnest and Helen Scott Haematological Institute. Models are being used to support GSK DPAc project - fully updated in other RF returns. Update February 2020. |
| Start Year | 2016 |
| Description | Structural Biology of the COP9 Signalosome |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Expertise in molecular activity/ binding assay, crystallography and fragment screening. |
| Collaborator Contribution | Domainex for a STAR award (awarded in July 2015 ~ value £10,000). This award has led to an in silico screen of the Domainex LeadBuilder library of 1.2 million collated 'lead-like' molecules. |
| Impact | The 2014/15 CiC award was used to optimise novel in-house assays to detect the catalytic activity of the COP9 complex. These data enabled the Leicester team to win a competitive award from Domainex (the STAR Award for in silico screening). Validation of the fragment hits that resulted from the Domainex in-silico screening has been performed by the Leicester team. Project outcome: No major outcome to claim. Activity assay completed but no evidence of binding. Crystallography based fragment screen performed in Leicester and at the EMBL in Grenoble - France (Oct 2018 - April 2019). 3 fragment hits identified that show concentration dependent activation activity. Further investigation needed. Partnership with Domainex ended in 2018. There will be no further follow-up due to the principal investigator leaving the University of Leicester. Update Feb2020. |
| Start Year | 2015 |
| Title | METHODS |
| Description | A method for improving skin scar colour matching, for example reducing scar hyperpigmentation, the method comprising administering a therapeutically effective amount of an agent, which positively modulates &bgr;2-adrenergic receptor conformation, or receptor activity, or activation thereof, to a subject in need thereof. The subject typically is in need of improving skin scar colour matching, for example reducing scar hyperpigmentation, because the subject has or is at risk of hyperpigmentation. The subject typically is selected as being at risk of hyperpigmentation on the basis of one or more of the following factors: · the subject has previously developed hyperpigmentation of a scar • the subject tans readily on exposure to sunshine or ultraviolet (UV) radiation, rather than burning • the subject has a non-Caucasian racial origin • the subject's skin colour (for example in an area that is not tanned) is considered to be darker than that typical of a naturally fair-haired Caucasian person. The subject may be selected as being at risk of hyperpigmentation because they are at least predominantly of Chinese, black African, Asian or Southern European racial origin, and/or if their skin type can be assessed under the Fitzpatrick Scale as Type III, IV, V or VI. |
| IP Reference | WO2014135896 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | This is the basis of an Biomedical catalyst funded first in man clinical trial of Salbutamol as a topical treatment. |
| Title | MODULATION OF FIBROBLAST ACTIVITY |
| Description | The invention includes a method for simultaneously decreasing the amount of TGFß1 and increasing the amount of TGFß3 produced by a fibroblast, the method comprising contacting the fibroblast with an agent which positively modulates ß2-adrenergic receptor; a method for reducing fibroblast differentiation, the method comprising contacting the fibroblast with an agent which positively modulates ß2-adrenergic receptor; and a method of reducing the deposition of collagen in a subject, the method comprising administering to the subject an agent which positively modulates ß2-adrenergic receptor. |
| IP Reference | WO2009118541 |
| Protection | Patent granted |
| Year Protection Granted | 2009 |
| Licensed | No |
| Impact | This was the basis for a MRC Biomedical catalyst funded first in man Phase I Clinical Trial of Salbutamol as a topical therapy. |
| Title | New compounds and uses |
| Description | A compound or a pharmaceutically acceptable salt of Formula I; Wherein L is C1-6 alkyl optionally substituted with one or more fluoro; X is O or S; each R1 is independently halo, Ra1, -CN, -Aa1-C(Qa1)Rb1, -Ab1-C(Qb1)N(Rc1)Rd1, -Ac1-C(Qc1)ORe1, -Ad1-S(O)pRf1, -Ae1S(O)pN(Rg1)Rh1, -Af1-S(O)pORi1, -N3, -N(Rj1)Rk1, -N(H)CN, -NO2, -ONO2, ORl1 or SRm1; each Qa1-Qc1 is independently =O, =S, =NRn1, =N(ORo1); each Aa1-Af1 is independently -N(Rp1)- or -O-; n is 0-4; each p is 1-2; R2 is -C(O)ORa2, -C(O)NRb2Rc2 or tetrazole; wherein Ra1-Rp1 and Ra2-Rc2 are as defined herein; provided the compound is not (6-chloro-5,7-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl) acetic acid or 3-(6-chloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl) propanoic acid). The compounds, including those covered by the proviso, are disclosed to be useful in the treatment of neurodegenerative and neuroinflammatory diseases. The use of the compound in combination products and kits-of-parts comprising one or more other therapeutic agent useful in the treatment of neurodegenerative and neuroinflammatory diseases is also disclosed. |
| IP Reference | GB2568549 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | This research has revealed a unique class of compounds which penetrate the blood brain barrier concentrating the active compound at the therapeutic site. This coudl be used as the basis for a number of additional neurogenerative therapies. |
| Title | SENESCENCE |
| Description | The invention provides an inhibitor of a Tec family tyrosine kinase and uses thereof. The invention also extends to methods of treating, ameliorating or preventing senescence or an age-related disorder or a solid tumour in a subject. The invention also extends to Tec family tyrosine kinase gene-silencing molecules, pharmaceutical compositions, methods of making the compositions and compound screening assays. |
| IP Reference | WO2016128744 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Another patent application has been granted: GB2015/051480 |
| Title | Phase I clinical trial of Salbutamol as a topical treatment to reduce scarring |
| Description | This is a topical gel formulation of Salbutamol, currently being assessed in a Phase I study. The therapy is intended to reduce scarring and hyper-pigmentation of wounds, in the case of this trial, a test incision of healthy volunteers. The trial is being funded by Biomedical Catalyst (Grant ref: MR/M024679/1). Update FEB2020: Trial recruitment is complete and has achieved its primary objective of patient safety, full analysis of efficacy data is ongoing (anticipated Q3 2020). |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2019 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | SSCART |
| Impact | This represents a unique re-purposing of a drug therapy from an inhaled asthma product to a topical wound healing modifier. The relative low cost of the active ingredient and excellent safety profile established after many years of use, mean that successful clinical trials should lead to a widely available product. A number of previous products to reduce scarring were high cost biologics that required injections to administer, this made their cost effectiveness very limited despite having some positive results. The completion of this phase I trial will position the product for further commercial investment or acquisition. |
| URL | https://clinicaltrials.gov/show/NCT03514615 |
| Description | CR-UK outreach |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Engagement with activities organised as part of the Cancer Research UK Leicester Centre. Typically bi-annual events are put on to engage with the general public with hands on activities, talks, films and discussions (inc Q&A sessions). |
| Year(s) Of Engagement Activity | 2015,2016 |
| Description | Girlguiding |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | multiple events within Girlguiding Leicestershire - 1) age appropriate hands on activities performed with girls from 4-17 to make science fun and engaging - with the purpose of promoting Science Technology Engineering and Maths (STEM) activities to young women (small groups - individual meetings and also to division/county events including camps and activity days) 2) training sessions for leaders in Girlguiding to enable/encourage them to undertake STEM activities within their units 3) to promote Women In Science and Engineering (WISE) 4) provide positive female role models |
| Year(s) Of Engagement Activity | 2015,2016,2017,2018 |
| Description | MCB Open Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Open day to school children from across the region for widening participation purposes. Hands on activities explaining 'precision medicine' were undertaken |
| Year(s) Of Engagement Activity | 2016,2017 |
| URL | http://www2.le.ac.uk/departments/molcellbiol/file-store/science-open-day-2016 |
| Description | Patient group talks |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Talks about advances in drug discovery research at the University (special emphasis on lung/thoracic and haematological diseases). Typically 'after dinner style' talks with Q&A sessions. |
| Year(s) Of Engagement Activity | 2015,2016,2017,2018 |
| Description | School visits |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Talks given on malaria research - typically to a year group (60-80 students) - discussions, Q&A sessions to follow and careers advice given. Typically 3-4 such events are undertaken annually. |
| Year(s) Of Engagement Activity | 2015,2016,2017,2018 |
| Description | School visits to UOL |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Participation in Dynamic DNA and Richard III open days - which open up the University to children and members of the general public. Typically a mixture of hands on activities (covering science subjects and other activities of note for the University e.g. archeology). The positive effects are increased engagement with the local (and wider community) and in widening participation (making a University education more approachable for all). |
| Year(s) Of Engagement Activity | 2015,2016,2017,2018 |